Browsing by Author "Gülbağcı, Burcu"
Now showing items 1-3 of 3
-
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study
Kahraman, Seda; Hızal, Mutlu; Demirel, Nurçin Çakan; Güven, Deniz Can; Gümüşay, Özge; Uluç, Başak Oyan; Bayram, Ertuğrul; Gülbağcı, Burcu; Yaşar, Alper; Davarcı, Sena Ece; Moçan, Eda Eylemer; Acar, Ömer; Işık, Deniz; Aydın, Esra; Karakaş, Yusuf; Özçelik, Melike; Keser, Murat; Okutur, Sadi Kerem; Eren, Önder; Menekşe, Serkan; Aydın, Dinçer; Yılmaz, Funda; Doğan, Özlem; Özkanlı, Gülhan; Yücel, Hakan; Sunar, Veli; Aybak, Musa Barış; Özdemir, Özlem; Duman, Berna Bozkurt; Keskinkılıç, Merve; Sakalar, Teoman; İnal, Ali; Karaoğlanoğlu, Müge; Aksoy, Asude; Er, Muhammed Muhiddin; Turhal, Nazım Serdar; Kalkan, Nurhan Önal; Sendur, Mehmet Ali Nahit (BMC, 2024)Highly selective inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6is) have emerged as a standart of care for first- and second-line therapies in combination with endocrine therapy (ET) for HR+/HER2- metastatic breast ... -
The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study
Özyurt, Neslihan; Alkan, Ali; Gülbağcı, Burcu; Seyyar, Mustafa; Aydın, Esra; Şahbazlar, Mustafa; Türker, Mehmet; Kınıkoğlu, Oğuzcan; Yerlikaya, Tahir; Dinç, Gülhan; Aytaç, Ali; Kalkan, Ziya; Ebinç, Senar; Gültürk, İlkay; Keskinkılıç, Merve; İşleyen, Zehra Sucuoğlu; Çağlayan, Dilek; Türkel, Alper; Şakalar, Teoman; Sekmek, Serhat; Yıldırım, Nilgün; Koçak, Sinem; Okutur, Kerem; Özveren, Ahmet; Dursun, Bengü; Kitaplı, Sait; Eren, Orhan Önder; Beypınar, İsmail; Hacıbekiroğlu, İlhan; Çabuk, Devrim; Karaman, Elanur; Acar, Ömer; Paydaş, Semra; Eryılmaz, Melek Karakurt; Demir, Bilgin; Oruç, Zeynep; Yılmaz, Mesut; Biricik, Fatih Selçuk; Salim, Derya Kıvrak; Tanrıverdi, Özgür; Doğan, Mutlu (Nature Research, 2024)The studies evaluating the impact of Her2 levels in neoadjuvant setting have conflicting data. The aim of the study was to evaluate the prognostic impact of Her2 status in early triple negative breast cancer(TNBC). In the ... -
Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish oncology group (TOG) study
Kahraman, Seda; Erul, Enes; Gümüşay, Özge; Güven, Deniz Can; Aksoy, Sercan; Başaran, Gül; Seyyar, Mustafa; Şahin, Elif; Çabuk, Devrim; Bayram, Ertuğrul; Paydaş, Semra; Demirel, Burçin Çakan; Yaren, Arzu; Gülbağcı, Burcu; Hacıbekiroğlu, İlhan; Baytemur, Naziyet Köse; Demirci, Umut; Davarcı, Sena Ece; Demir, Hacer; Mocan, Eda Eylemer; Doğan, Özlem; Çılbır, Ebru; Yaşar, Alper; Bayoğlu, İbrahim Vedat; Hızal, Mutlu; Kayıkcıoğlu, Erkan; Çetin, Bülent; Acar, Ömer; Erdoğan, Atike Pınar; Keskinkılıç, Merve; Yavuzşen, Tuğba; Ünal, Olcun Ümit; Yılmaz, Funda; Doğan, Mutlu; Orhan, Sibel Oyucu; Çubukcu, Erdem; Erol, Cihan; Sakalar, Teoman; Dulgar, Özgecan; Karakaş, Yusuf; Özkanlı, Gülhan; Duman, Berna Bozkurt; Isık, Deniz; Karaoğlanoğlu, Müge; Okutur, Sadi Kerem; Yıldırım, Nilgün; Aydın, Esra; Uluç, Başak Oyan; Keser, Murat; Bilgin, Burak; Aksoy, Asude; Eren, Önder; Kalkan, Nurhan Önal; Er, Muhammed Muhiddin; Yücel, Hakan; Sunar, Veli; Paksoy, Nail; Aydın, Dinçer; Turhal, Nazım Serdar; Menekşe, Serkan (Elsevier, 2025)Background: Real-world (RW) data provide valuable information about the effectiveness and safety of treatment modalities in the general population that is not limited by selection criteria in clinical studies. The aim of ...
